Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Sort descending Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Renflexis infliximab rheumatoid arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, fistulising Crohn’s disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis Reimburse with clinical criteria and/or conditions Complete
Erelzi Etanercept Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Xalkori Crizotinib ROS1-positive advanced non-small cell lung cancer (NSCLC) Reimburse with clinical criteria and/or conditions Complete
Rozlytrek Entrectinib ROS1-positive NSCLC Reimburse with clinical criteria and/or conditions Complete
Rosiver Ivermectin Rosacea List with criteria/condition Complete
Finacea Azelaic acid Rosacea List Complete
Apprilon Doxycycline monohydrate Rosacea Do not list Complete
Vraylar cariprazine Schizophrenia Do not reimburse Complete
Invega Paliperidone Schizophrenia Do not list Complete
Abilify Aripiprazole Schizophrenia Do not list Complete